Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib.
Colorectal neoplasms
Drug resistance
MicroRNAs
gefitinib
regorafenib
Journal
Iranian journal of medical sciences
ISSN: 0253-0716
Titre abrégé: Iran J Med Sci
Pays: Iran
ID NLM: 8104374
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
ppublish
Résumé
Usually, chemoradiotherapy can be used for the treatment of locally advanced colorectal cancer (CRC) before surgery. On the other hand, some studies have shown that fractional radiation of tumor cells leads to chemoresistance. The aim of this study was to evaluate the chemoresistance of radioresistant sub-line (RR sub-line). This study was done in The IC50 of gefitinib and regorafenib for RR sub-line were significantly higher than those of the parental cell line. On the other hand, the resistance index of RR sub-line for gefitinib and regorafenib were 1.92 and 1.44, respectively. The sub-G1 fraction of RR sub-line following treatment with gefitinib and regorafenib was significantly lower than that of the parental cell line (P=0.012 and P=0.038, respectively). The expression of miR-9, Let-7e, and Let-7b in RRsub-line was significantly lower than that of the parental cell line. However, NRAS, IGF1R, NFKB1, and CCND1 found to be upregulated in RR sub-line in comparison with the parental cell line. We can conclude that the acquired RR sub-line was cross-resistance to gefitinib and regorafenib. Furthermore, miR-9/NFKB1, let-7b/CCND1, let-7e/NRAS, and IGF1R played essential roles in the chemoradioresistance of CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Usually, chemoradiotherapy can be used for the treatment of locally advanced colorectal cancer (CRC) before surgery. On the other hand, some studies have shown that fractional radiation of tumor cells leads to chemoresistance. The aim of this study was to evaluate the chemoresistance of radioresistant sub-line (RR sub-line).
METHODS
METHODS
This study was done in
RESULTS
RESULTS
The IC50 of gefitinib and regorafenib for RR sub-line were significantly higher than those of the parental cell line. On the other hand, the resistance index of RR sub-line for gefitinib and regorafenib were 1.92 and 1.44, respectively. The sub-G1 fraction of RR sub-line following treatment with gefitinib and regorafenib was significantly lower than that of the parental cell line (P=0.012 and P=0.038, respectively). The expression of miR-9, Let-7e, and Let-7b in RRsub-line was significantly lower than that of the parental cell line. However, NRAS, IGF1R, NFKB1, and CCND1 found to be upregulated in RR sub-line in comparison with the parental cell line.
CONCLUSION
CONCLUSIONS
We can conclude that the acquired RR sub-line was cross-resistance to gefitinib and regorafenib. Furthermore, miR-9/NFKB1, let-7b/CCND1, let-7e/NRAS, and IGF1R played essential roles in the chemoradioresistance of CRC.
Identifiants
pubmed: 32038059
doi: 10.30476/ijms.2019.44972
pii: IJMS-45-1
pmc: PMC6983275
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50-58Informations de copyright
Copyright: © Shiraz University of Medical Sciences.
Références
Jpn J Radiol. 2017 Nov;35(11):664-672
pubmed: 28879560
Cancers (Basel). 2013 Aug 09;5(3):998-1019
pubmed: 24202331
Expert Opin Ther Targets. 2009 Mar;13(3):339-62
pubmed: 19236156
Crit Rev Oncol Hematol. 2014 Feb;89(2):300-13
pubmed: 24041630
Oncol Rep. 2017 Apr;37(4):2193-2200
pubmed: 28260112
Oncogene. 2006 Oct 30;25(51):6831-43
pubmed: 17072331
Oncotarget. 2017 Jul 6;8(35):59950-59964
pubmed: 28938696
Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):109-27
pubmed: 19451095
Cell Cycle. 2015;14(13):2171-80
pubmed: 25714397
Drug Resist Updat. 2011 Dec;14(6):280-96
pubmed: 21955833
Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):213-6
pubmed: 1991681
Oncol Rep. 2014 Aug;32(2):787-93
pubmed: 24919435
J Cell Physiol. 2006 Jul;208(1):220-8
pubmed: 16575905
Biochim Biophys Acta. 2007 Aug;1773(8):1177-95
pubmed: 17428555
Gastroenterology. 2013 Nov;145(5):1133-1143.e12
pubmed: 23916944
Transl Res. 2014 Nov;164(5):411-23
pubmed: 25016932
PLoS One. 2013 Aug 19;8(8):e72119
pubmed: 23977225
World J Gastrointest Oncol. 2017 May 15;9(5):209-217
pubmed: 28567185
Cell Biol Int. 2011 Jul;35(7):721-5
pubmed: 21241250
Biomed Pharmacother. 2016 Aug;82:528-36
pubmed: 27470393
Anticancer Res. 2012 Jan;32(1):121-8
pubmed: 22213296
Int J Cancer. 2008 Dec 15;123(12):2939-49
pubmed: 18803287
Int J Oncol. 2016 May;48(5):2135-43
pubmed: 26983891
Hum Exp Toxicol. 2016 May;35(5):526-43
pubmed: 26183715
Oncotarget. 2017 Feb 21;8(8):13253-13263
pubmed: 28129648
Radiother Oncol. 2013 Sep;108(3):451-7
pubmed: 23932154
Expert Opin Pharmacother. 2016;17(1):137-45
pubmed: 26559195
Eur J Cancer. 2010 Jan;46(2):298-311
pubmed: 19948396
Am J Cancer Res. 2015 Jan 15;5(2):545-59
pubmed: 25973296
Nat Protoc. 2006;1(3):1458-61
pubmed: 17406435
J Hepatol. 2010 May;52(5):698-704
pubmed: 20347499
J Cell Physiol. 2013 Feb;228(2):292-7
pubmed: 22777740
Cancer Res. 2015 Jun 15;75(12):2489-500
pubmed: 25870145
Curr Mol Med. 2011 Mar;11(2):93-109
pubmed: 21342132
Methods Mol Biol. 2004;281:301-11
pubmed: 15220539
J Ovarian Res. 2017 Apr 4;10(1):24
pubmed: 28376831
Clin Cancer Res. 2016 Apr 1;22(7):1767-76
pubmed: 26561558